COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Track Record

Showing latest 4 periods • Swipe for more

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	780.57M	631.45M	566.77M	463.93M	276.87M	310.02M	296.70M	280.41M	28.48M	1.71M	0	0
Net Income	62.87M	69.19M	48.16M	(25.00M)	71.52M	26.75M	(22.72M)	(39.13M)	(74.86M)	(94.18M)	(27.25M)	(17.92M)
EPS	1.98	2.14	1.60	-0.74	2.05	0.78	-0.24	-1.19	-2.47	-3.88	-2.01	-2.40
Free Cash Flow	327.58M	203.33M	274.29M	122.61M	101.61M	(279.83M)	21.34M	145.04M	(68.01M)	(78.03M)	N/A	N/A
FCF / Share	10.33	6.30	8.13	3.62	2.91	-8.13	0.64	4.41	-2.25	-3.22	N/A	N/A
Operating CF	329.32M	204.98M	274.75M	124.23M	103.56M	93.94M	27.78M	169.39M	(67.02M)	(75.05M)	N/A	N/A
Total Assets	1.66B	1.66B	1.14B	1.17B	692.08M	643.84M	306.30M	291.25M	135.57M	162.02M	N/A	N/A
Total Debt	940.56M	859.30M	674.28M	709.17M	258.75M	266.58M	21.59M	11.50M	1.48M	4.15M	N/A	N/A
Cash & Equiv	251.10M	70.56M	238.95M	173.69M	186.43M	174.12M	170.02M	146.63M	118.70M	153.22M	N/A	N/A
Book Value	301.68M	228.84M	195.43M	194.84M	202.93M	186.03M	87.43M	91.58M	104.08M	134.91M	N/A	N/A
Return on Equity	0.21	0.30	0.25	-0.13	0.35	0.14	-0.26	-0.43	-0.72	-0.70	N/A	N/A

Metric	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023
Revenue	193.52M	205.45M	209.36M	188.00M	177.76M	181.95M	159.30M	145.28M	144.92M	149.75M	136.71M	135.55M
Net Income	14.50M	16.96M	31.51M	11.98M	2.42M	12.54M	9.34M	19.61M	27.71M	31.94M	20.63M	13.01M
EPS	0.45	0.54	1.00	0.38	0.08	0.39	0.33	0.60	0.86	0.99	0.61	0.38
Free Cash Flow	56.84M	122.36M	78.25M	72.37M	54.60M	84.07M	(9.24M)	67.13M	61.37M	73.17M	73.95M	99.67M
FCF / Share	1.77	3.86	2.48	2.28	1.72	2.62	-0.29	2.07	1.90	2.27	2.19	2.88
Operating CF	57.11M	123.05M	78.44M	72.44M	55.40M	84.64M	(9.00M)	67.40M	61.94M	73.34M	74.02M	99.72M
Total Assets	1.65B	1.66B	1.61B	1.59B	1.63B	1.66B	1.64B	1.05B	1.11B	1.14B	1.18B	1.21B
Total Debt	808.06M	940.56M	936.27M	829.11M	844.21M	859.30M	874.39M	559.46M	629.99M	674.28M	718.39M	762.35M
Cash & Equiv	268.65M	251.10M	169.95M	117.35M	96.19M	70.56M	38.96M	172.89M	228.61M	238.95M	258.53M	283.75M
Book Value	312.42M	301.68M	274.81M	232.21M	234.43M	228.84M	234.28M	216.58M	222.17M	195.43M	178.87M	200.81M
Return on Equity	0.05	0.06	0.11	0.05	0.01	0.05	0.04	0.09	0.12	0.16	0.12	0.06